been shown to include periods of cerebral vasoconstriction as part of its pathophysiological characteristics. 10, 11, 13, 17 Experimentally, high-dose Mg has been shown to reverse vasospasm induced in the rat SAH model. 9 Infusions of MgSO 4 have been well tolerated in patients suffering from preeclampsia and eclampsia, acute stroke, and cardiac arrhythmias. 2, 10, 12, 14, 15 The safety and effectiveness of MgSO 4 in preventing vasospasm and improving neurological outcome following aneurysmal SAH has only recently been reported. 4 We present the results of a prospective randomized single-blind (that is, patient-blinded) pilot study of MgSO 4 therapy in patients with SAH. The objectives of our study were threefold: 1) to assess the safety of MgSO 4 infusions in patients with SAH by monitoring hemodynamic indices and the effect on serum electrolytes; 2) to assess the effectiveness of MgSO 4 in preventing vasospasm in aneurysmal SAH, as judged by cerebral blood flow velocities by using TCD ultrasonography, and cerebral angiography in patients with clinical evidence of delayed ischemia; and 3) to assess the effectiveness of MgSO 4 in improving neurological outcomes in patients 3 months following SAH by determination of the patient's GOS score. 5 
Clinical Material and Methods
We performed a prospective randomized placebo-controlled patient-blinded pilot study to examine the safety and to compare the effect of MgSO 4 therapy in preventing vasospasm and improving neurological outcome after aneurysmal SAH. The human rights committee at our institution approved the study protocol. Patients were considered eligible for the study if they met the following criteria: presentation less than 72 hours post-SAH (confirmed by computerized tomography and angiography studies), a Hunt and Hess score of II to IV on admission, an age older than 18 years, and informed consent. Ineligible patients included those with any of the following conditions, which relate to known adverse clinical effects of hypermagnesemia: pregnancy, congestive heart failure (New York Heart Association Class 3 or 4), renal insufficiency with a calculated creatinine clearance rate of less than 30 ml/minute, known neuromuscular disease (such as myesthenia gravis or myotonic dystrophy), concomitant use of neuromuscular blocking agents, serum K ϩ level greater than 5.5 mg/dl, serum Ca ϩϩ level lower than 0.9 mg/dl, or hypotension (systolic pressure Ͻ 90 mm Hg or mean arterial blood pressure Ͻ 60 mm Hg) unresponsive to intravenous administration of fluid and/or pressors.
Forty patients were enrolled in the study: 20 (15 female and five male patients, with a mean age of 46 years) in the treatment group and 20 (11 female and nine male patients, with a mean age of 51 years) in the control group. Following randomization, patients in the treatment group received MgSO 4 infusion, which was initiated with a bolus of 6 g in a 250-ml solution of 0.9% NaCl over 30 minutes, followed by continuous infusion at 2 g/hour (40 g in a 1000-ml solution of 0.9% NaCl at 50 ml/hour). Subsequent dosage adjustments in the MgSO 4 infusion were made to maintain a target Mg ϩϩ level of 4 to 5.5 mg/dl (normal serum Mg ϩϩ level 1.5-2 mg/dl). If serum Mg ϩϩ was less than 4 mg/dl or between 5.5 and 7.1 mg/dl, the infusion was increased or decreased, respectively, by 0.5 g/hour (12 ml/hour). If the serum level of Mg ϩϩ was greater than 7.1 mg/dl, the infusion was suspended until the level decreased below 7 mg/ dl, after which the infusion was restarted at 1 g less per hour (25 ml/hour). Patients in the control group received an intravenous placebo consisting of a 250-ml solution of 0.9% NaCl over a 30-minute period, followed by continuous infusion of 0.9% NaCl at 50 ml/hour. Patients received either MgSO 4 or placebo for either 10 days or until discharge from the ICU, whichever was shorter.
Initially, patients in both groups received standard care and management of aneurysmal SAH in our neurosurgical ICU. Standard medical care included administration of nimodipine, phenytoin, triple-H therapy, and mannitol, with or without pentobarbital if needed for ICP control. Early securement of the aneurysm was performed using surgery or endovascular technique.
While in the ICU, patients received daily monitoring for vasospasm with the aid of TCD ultrasonography recordings and neurological and motor examinations. Maximum and mean flow velocities of the right MCA were measured through the temporal bone window. The mean values for maximum and mean daily MCA velocities were calculated for each patient over the entire study period (10 days from the time of admission). Clinical vasospasm was defined as a new focal neurological deficit that could not be accounted for by other causes such as hydrocephalus, hematoma, seizure, or electrolyte abnormality. Motor strength was assessed using the standard five-point scale. Routine ICU monitoring also included compilation of records on hemodynamic parameters, 24-hour input/output measurements, ventilator settings, intracranial pressure monitoring if available, and serum electrolytes. The patient's serum Mg ϩϩ level was checked 6 hours after a dose change and every 12 hours thereafter. Patients in the placebo group received routine infusions of MgSO 4 if their serum Mg ϩϩ levels were lower than 2 mg/dl. All patients received Ca gluconate if serum Ca ϩϩ was less than 0.9 mg/dl. Following discharge from the ICU, patients underwent daily neurological assessment. A GOS score (5, good recovery; 4, moderate disability but independent; 3, severe disability; 2, persistent vegetative state; or 1, death) was recorded at the 3-month follow-up examination.
To analyze the results of our trial, we focused on the patients' GOS scores as a measure of the effectiveness of MgSO 4 for prevention of long-term sequelae of vasospasm from aneurysmal SAH. We considered a GOS score of 4 or 5 as ideal, as this confers functional independence. The GOS data and TCD recordings were analyzed using the independent t-test.
Results
Clinical data are summarized in Table 1 and mean values for groups are given as the means Ϯ SD in both tables and text. Patient characteristics were similar in both groups. Four patients in the control group were withdrawn from the study because study requirements were not met. In one excluded patient, no aneurysm was found at the time of surgery, but instead a slightly dilated anterior communicating artery and A 1 segment were discovered and these were wrapped with cotton fibers during surgery. Another patient who had been randomized to the control group was mistakenly given a bolus infusion of MgSO 4 . We also excluded a patient whose onset of symptoms was discovered to have been outside the 72-hour enrollment window. Last, one elderly patient was removed from the study when he experienced congestive heart failure and could not tolerate the additional intravenous fluid required for placebo infusion.
Magnesium sulfate did not significantly lower mean arterial blood pressure during bolus or continuous infusion on any day during the treatment period (all p Ͼ 0.05, Student t-test). All patients achieved Mg ϩϩ levels within the target range with adjustments in the infusion rate; the mean Mg ϩϩ level was 4.6 Ϯ 0.76 (mean Ϯ SD) and the mean infusion rate was 1.5 Ϯ 0.47 g/hour. Mean serum total Ca ϩϩ levels were lower in patients in the treatment group (6.8 Ϯ 0.71 compared with 7.9 Ϯ 0.61, p = 0.02) and required supplementation. Magnesium and Ca ϩϩ levels and supplementation data are shown in Table 2 . Clinical Hunt and Hess grades were 2.6 Ϯ 0.68 in the treatment group and 2.3 Ϯ 0.73 in the control group (p = 0.87). There was no significant reduction in mean MCA velocity, incidence of symptomatic vasospasm, or clinical outcome in the treatment group. Mean MCA velocity was 93 Ϯ 27 cm/second in the treatment group and 102 Ϯ 34 cm/second in the control group (p = 0.41). Mean maximum MCA velocity was 144 Ϯ 48 cm/second in the treatment group and 149 Ϯ 57 cm/second in the placebo group (p = 0.77). Subgroup analysis of patients with Hunt and Hess Grade II SAH revealed an average maximum MCA velocity of 162 Ϯ 59 cm/second in treated patients compared with 155 Ϯ 49 cm/second in control patients (p = 0.78). Likewise, in the subgroup of patients with Hunt and Hess Grades III and IV hemorrhages, no difference in average maximum MCA velocity was seen (133 Ϯ 53 cm/second compared with 134 Ϯ 46 cm/ second, p = 0.98).
No significant reduction in the incidence of symptomatic vasospasm was seen; it occurred in six of 20 patients receiving MgSO 4 and in five of 16 patients receiving placebo (p Ͼ 0.84, Student t-test). Angiography confirmed the presence of vasospasm in all cases and was defined as mild, moderate, or severe arterial narrowing. In 80% of patients in the control group who had symptomatic spasm, severe arterial narrowing was revealed by angiography, compared with 77% in the group receiving MgSO 4 . Two patients in the MgSO 4 treatment group experienced symptomatic spasm in the absence of elevated MCA velocities measured using TCD ultrasonography (that is, Ͻ 120 cm/second), compared with one patient in the control group. Conversely, four patients in the Mg treatment group in whom TCD ultrasonography documented increased MCA velocities failed to experience clinical vasospasm, whereas three patients in the control group remained asymptomatic despite elevated MCA velocities. Significant adverse effects from Mg treatment did not occur. Early in the study two patients experienced transient diplopia and muscle weakness when serum Mg ϩϩ levels rose above 6 mg/dl; however, once Mg ϩϩ levels were maintained within the 4 to 5.5 mg/dl range, these patients' symptoms resolved. Deaths among patients in the treatment group were due to brain ischemia or edema in three patients and rupture of the carotid artery during angioplasty in one patient. Deaths in patients in the placebo group were due to massive myocardial infarction 2 weeks postoperatively in one patient and malignant cerebral edema in one patient.
Mean GOS scores for all patients in the treatment and control groups were 3.8 Ϯ 1.6 and 3.6 Ϯ 1.5 (p = 0.74), respectively. Among patients with Hunt and Hess Grade II SAH, a higher percentage of those receiving MgSO 4 had a GOS score of 4 or 5 compared with those receiving placebo, although this did not reach statistical significance (90% compared with 67%, p = 0.21). Table 3 summarizes the subgroup analysis data, showing the trend toward improved neurological outcomes.
Discussion
The clinical use of intravenous MgSO 4 in prevention of vasospasm following aneurysmal SAH was investigated in this randomized prospective pilot trial. The use of MgSO 4 was safe and target levels were easily maintained, but no benefit was observed in the proposed end points, which included TCD recordings, incidences of symptomatic vasospasm, and ultimate GOS scores.
Vasospasm remains a significant source of morbidity and mortality following aneurysmal SAH, despite advances in current medical, surgical, and endovascular therapies. Calcium-channel antagonists have significantly reduced the neurological sequelae of symptomatic vasospasm. 1 Despite the use of triple-H therapy with colloids, crystalloids, and pressors to augment cerebral blood flow, 25 to 35% of patients who have suffered an SAH may still experience permanent neurological effects from delayed cerebral isch- Hypermagnesemia may result in other pronounced effects on respiratory function, cardiac conduction and contractility, neuromuscular transmission, and electrolytes. Magnesium at toxic levels (14-15 mg/dl) can produce respiratory depression, heart block, and cardiac arrest. 2, 8 Lower levels of hypermagnesemia have been associated with arrhythmias and worse outcomes in patients following acute myocardial infarction with heart failure. High levels of Mg ϩϩ have been shown to act as a negative ionotrope, which may become quite significant in patients with advanced heart failure. 2 In patients with preexisting disorders of neuromuscular transmission, Mg ϩϩ may exacerbate weakness. 3 High dosages of Mg ϩϩ have also been shown rarely to increase K ϩ and lower Ca ϩϩ levels. 12 The effect of Mg on reversing vasospasm in an animal SAH model has been studied. Ram, et al., 9 simulated SAH by intracisternal injection of blood in the rat. Infusion of intravenous MgSO 4 dilated the spastic basilar artery by approximately 75% of the baseline diameter in control rats (p Ͻ 0.0001). In that study the plasma Mg ϩϩ levels in treated animals reached 2.5 mg/dl compared with 0.9 mg/dl in control rats. 7 The study of Mg in the prevention of cerebral vasospasm following human SAH has only recently been reported. Boet and Mee 4 studied the clinical course of 10 patients who presented with Fisher Grade 3 hemorrhage in an unblinded noncontrolled pilot study to judge the safety and effectiveness of MgSO 4 infusion. No adverse events were noted during the infusions. 4 Our study documents the first prospective, randomized, single-blind pilot trial. We examined the safety and effectiveness of intravenous administration of MgSO 4 in neurosurgical patients, and measured its efficacy for prevention of vasospasm and improvement in neurological outcome. This treatment had no adverse effects when serum levels ranged between 4 and 5.5 mg/dl. Use of MgSO 4 did not interfere with neurological evaluation, hemodynamic stability, or respiratory function. The serum level of Mg ϩϩ could be readily maintained with relatively few adjustments in infusion rate over the 10-day treatment period. Overall outcome measures of MCA velocity determined using TCD ultrasonography, incidence of posthemorrhage vasospasm, and GOS scores demonstrated no significant improvement in patients who received MgSO 4 compared with control patients; however, data obtained in our treated patients did reveal a trend (albeit not a statistically significant one) toward a higher percentage of patients attaining a GOS score of 4 or 5. The 40 patients comprising our pilot trial were an insufficient number to obtain statistical significance. For the percentage of patients in our study who had a GOS score of 4 or 5 to reach significance, we estimate that 170 patients per group (MgSO 4 compared with placebo, Hunt and Hess Grades II-IV) would be needed to achieve the 80% power required for the observed difference. Such numbers would be ideal for further investigations of MgSO 4 in a prospective randomized multicenter trial.
In summary, our clinical trial has shown that high-dose MgSO 4 therapy is safe in neurosurgical patients with SAH and that target therapeutic levels are easily achieved. Although we did not observe any benefit conferred by Mg ϩϩ on patients in this pilot trial with respect to MCA velocity, clinical vasospasm, or ultimate GOS score, we did observe a trend in patients with Hunt and Hess Grade II SAH to have improved neurological outcomes at 3 months posthemorrhage. A larger study is warranted to investigate this trend further. 
